



PATENT  
Docket No.: CL/V-31346/A  
Cust. No. 001095

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.

Jennifer China  
Type or print name

Signature

Date

*Jennifer China* Feb 3, 2003

#7  
2/14/03  
90

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

**LEUJEL, ET AL.**

APPLICATION NO: **09/802,757**

FILED: **MARCH 09, 2001**

FOR: **REACTIVE POLYMERS**

EXAMINER:

**S. BERMAN**

ART UNIT: **1711**

Honorable Commissioner for Patents  
Washington, D.C. 20231

February 03, 2003

RECEIVED  
FEB 13 2003  
TC 1700 MAIL ROOM

**RESPONSE TO RESTRICTION REQUIREMENT**


Sir:

The Restriction/Election Requirement dated October 02, 2002 from Examiner S. Berman of Art Unit 1711 has been received and reviewed. The following is in response thereto.

**ELECTION**

Applicants elect the invention of Group I (Claims 1 – 8) drawn to a compound of formula I for examination.

Applicants select a compound of the formula (1), according to Claim 7 (corresponding to Example 3, DMA telomere of Example 2.1 ( $m_n$  3800)), wherein  $n = 0$ , A is CONH, and Z is a radical of formula



Application No.: 09/802,757


wherein  $R_5$  is  $CF_3$ , and (oligomer) denotes the radical of a telomere of formula (3a') wherein (alk) is  $(CH_2CH_2)$ ,  $R_9$  and  $R_9'$  are hydrogen,  $R_{10}$  and  $R_{10}'$  are  $-CON(CH_3)_2$ ,  $q$  is zero, the total of  $(p+q)$  is about 38, and  $Q$  is a hydrogen radical.

### CONCLUSION

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned.

Please address all correspondence to Novartis Corporation, Corporate Intellectual Property, One Health Plaza, Bldg. 430, East Hanover, NJ 07936-1080. The commissioner is hereby authorized to charge any other fees with may be required under 37 C.F.R. §1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Respectfully submitted,



Robert J. Gorman, Jr.  
Reg. No. 41,789  
(678) 415.4389

Novartis Corporation  
Corporate Intellectual Property  
One Health Plaza, Bldg. 430  
East Hanover, NJ 07936-1080

s:\jc legal department\public\patents\prosecut\31346\response to restriction requirement.doc